Every year, World Toilet Day is observed to raise awareness about the global sanitation crisis and encourage action to solve it. The goal set by the United Nation is to achieve safe toilets for all by 2023, as a part of their Sustainable Development Goals.

The UN also states that 3.5 billion people live without proper sanitation and many children also lose their lives due to poor sanitation and unsafe water. This is why World Toilet Day is observed to raise awareness on this issue.

Theme

This year, the theme for World Toilet Day 2024 is "Toilets - A Place for Peace'. This focuses on the growing threat to sanitation that is caused by conflict, climate change, disaster and neglect. When there is a threat to using toilets, it can lead to many health risks.

Not using toilets for too long may lead to Urinary Tract Infection or UTI. For many who do not have access to clean toilets do not drink enough liquid or hold pee for too long. Doctors suggest that holding in pee for too long can cause bacteria to multiply and lead to UTI. By not drinking enough water, your bladder fails to tell the body to pee often, and can cause the bacteria to spread through the urinary tract, which can lead to infection.

Symptoms of UTI:

• Burning or stinging feeling while urinating
• Pain in pelvis or lower abdomen
• Constant urge to empty the bladder
• Strong or foul smelling urine
• Consistently dark urine
• Blood in urine

Holding in pee for too long can also cause your bladder to stretch, making it difficult or even impossible for the bladder to contract and release pee normally. It can also damage your pelvic floor muscles or could lead to kidney stones.

World Toilet Day History And Significance

To prevent such conditions, it is important that everyone has access to clean and safe toilets. In terms of history, the day was established in 2001, by the World Toilet Organization (WTO), which was founded by Jack Sim. However, it was officially recognised by the UN in 2013. The Government of Singapore worked with WTO to create the first UN resolution called Sanitation for All.

India too promotes safe and hygiene toilet through its Swachh Bharat Yojna.

Russia today claimed that its scientists have developed a novel vaccine against a new Ebola strain.

According to Russian Health Minister Murashko, "the vaccine may also protect against the rare Bundibugyo strain linked to the current outbreak in the DR Congo".

It is because the "genetic similarity between this virus variant and the vaccine strain is about 60-70%," Alexander Gintsburg, scientific director of the Gamaleya National Center of Epidemiology and Microbiology, was quoted as saying GxP News.

The vaccine, for which "clinical trials would take place, as per Anne Ancia, the WHO’s representative in the DRC, comes as a hope against the Bundibugyo strain, with no vaccine or antiviral available.

The strain has so far caused over 900 cases and more than 200 deaths in the Democratic Republic of the Congo and Uganda.

Earlier this week, Russia’s consumer health watchdog Rospotrebnadzor announced it would send specialists to Africa to help fight the Ebola outbreak, GxP News reported.

The country noted that it will also supply Russian-developed diagnostic tests.

Health Minister Murashko said he and WHO Director-General Tedros Adhanom Ghebreyesus had discussed the supply of Russian vaccines to the DRC and Uganda in the context of the Ebola outbreak.

“Specialists are already deploying to provide assistance. We discussed this with Dr Tedros, the head of the World Health Organisation,” Murashko said.

Gintsburg believes that "medical workers in outbreak zones should be vaccinated with the existing vaccine, even though no targeted efficacy tests against this strain have been conducted".

He also stressed the need to develop a separate vaccine against Bundibugyo. However, the institute does not yet have a sample of this pathogen.

“I believe the existing vaccine may confer immunity against this pathogen, though we have not tested it. In the absence of other means, it should be used,” he told Izvestia, a Russian Newspaper.

Ebola Vaccine From Developers Of COVID Shot

Scientists at Oxford University are also developing a new vaccine that could be ready for clinical trials within two to three months to help tackle the Ebola emergency.

The vaccine uses the same technology the team developed during the COVID pandemic. It is a highly adjustable technology - known as ChAdOx1 - that can be quickly tweaked so it works against different infections.

Another separate experimental Bundibugyo vaccine is also in development, but it is expected to take six to nine months for any dose of that to be ready for testing, BBC reported.

Ebola: An Antiviral On The Anvil

The WHO has also recommended prioritizing two monoclonal antibodies for clinical trials.

"We are also recommending the evaluation of the antiviral obeldesivir in a clinical trial as post-exposure prophylaxis for people who are high-risk contacts," the WHO chief said.

This clinical trial is now being developed jointly with Africa CDC and the Collaborative Open Research Consortium on filoviruses, he noted.

How Ebola Spreads

Ebola disease is a severe viral hemorrhagic fever with a high mortality rate.

Ebola spreads through:

• Direct contact with infected blood or bodily fluids

• Contact with contaminated surfaces or medical equipment

• Unsafe caregiving exposure

• Traditional burial practices involving direct contact

• Certain zoonotic animal exposures.

Symptoms to watch for includes:

• fever,

• weakness,

• headache,

• muscle pain,

• vomiting,

• diarrhea,

• sore throat,

• unexplained bleeding.

India's southern state of Karnataka has reported a suspected case of Ebola Virus Disease (EVD) in a 28-year-old woman who returned from Uganda, which is currently experiencing an Ebola outbreak.

The woman who arrived in Bengaluru from Kampala, Uganda, on May 23, was suspected of infection after developing mild symptoms, including body ache, health officials said..

She was shifted from a hotel to the state-run Epidemic Diseases Hospital on May 26, 2026, according to The Hindu. Her test results are awaited.

Her blood samples and other required specimens were collected today and sent to a specialized laboratory in Pune for detailed testing. Health department officials are currently awaiting the medical report, which is expected by Wednesday.

Authorities said only after the laboratory results arrive can it be officially confirmed whether the woman is infected with the Ebola virus.

Ebola Virus Disease has caused over 900 cases and more than 200 deaths in the Democratic Republic of the Congo and Uganda, as per the World Health Organization (WHO). According to the WHO chief, Tedros Adhanom Ghebreyesus. The global health agency has also determined that the deadly outbreak is a “Public Health Emergency of International Concern (PHEIC)”.

“With air travel being common and the outbreak already having spread to multiple countries in Africa, it is entirely possible for someone who had contact with a person with Ebola virus disease to get on a flight to another country,” Dr. Rajeev Jayadevan, Co-Chairman of the National IMA COVID Task Force and Past President of the Indian Medical Association, Cochin, told HealthandMe.

“All patients with Ebola disease may not know they have it — as the initial symptoms are nonspecific such as fever and body ache. In addition, scarcity of the exact PCR test to diagnose the latest Bundibugyo Ebola virus in Africa makes it possible to miss it entirely,” he added.

India’s Preparedness

The suspected case comes as India has been ramping up screening and surveillance measures across the country, especially at airports and seaports.

Recently, the Karnataka government also issued guidelines for passengers arriving from Ebola-affected countries. As part of the precautionary measures, travelers entering Bengaluru from such nations are required to undergo a 21-day quarantine period.

People showing symptoms have been advised to immediately report to the nearest hospital. The Health Department has also directed strict surveillance and monitoring of suspected cases under the Integrated Disease Surveillance Programme (IDSP).

Also read: WHO Chief Warns Ebola Epidemic ‘Outpacing Us’; India Intensifies Screening At Airports

Officials have strengthened coordination at airports and other entry points to monitor international passengers. Separate quarantine and isolation facilities, along with referral ambulance services, have also been kept ready.

The Health Department has additionally instructed hospitals to enhance infection-control measures and provide special training to healthcare workers to handle any possible emergency situation.

The country has also issued a travel advisory for citizens to avoid non-essential travel to the Democratic Republic of the Congo, Uganda, and South Sudan.

How Ebola Spreads

Ebola spreads through:

• Direct contact with infected blood or bodily fluids
• Contact with contaminated surfaces or medical equipment
• Unsafe caregiving exposure
• Traditional burial practices involving direct contact
• Certain zoonotic animal exposures.

• fever,
• weakness,
• headache,
• muscle pain,
• vomiting,
• diarrhea,
• sore throat,
• unexplained bleeding.

People suffering from shingles after COVID-19 infection may be at a higher risk of neurological conditions such as Bell’s palsy, Guillain-Barré syndrome (GBS), as well as Myasthenia gravis (MG), according to a large study.

Shingles (also known as herpes zoster) is a painful condition caused by the varicella zoster virus that lives in the nervous system of people who have had chicken pox.

The study, led by researchers from Taiwan and Australia, showed that Bell’s palsy risk increased early after shingles. At the same time, GBS and MG showed delayed increases emerging more than a year later.

GBS, Bell’s palsy, and MG are all neurological conditions that cause muscle weakness, but they affect different parts of the nervous system. While GBS and MG cause widespread muscle weakness, Bell’s palsy is strictly localized to the face.

The findings, published in International Journal of Medical Sciences, highlighted “the need for symptom-based neurological awareness during both early and delayed post-infectious periods,” the researchers said.

What Did The Study Find?

Also read: ‘Heat Dome’ Triggering Record-Breaking May Temperatures In France, UK, Spain

During the COVID-19 pandemic, shingles was reported to occur in people with COVID-19 and in COVID-19 vaccine recipients; shingles vaccination programs were also disrupted.

The increased incidence of shingles following COVID-19 suggests a period of immune dysregulation, but the associated long-term neuro-immunological risks remain unclear.

To better understand this, researchers from Taipei Tzu Chi Hospital and Queensland University of Technology used electronic health records and compared COVID-19 survivors with individuals with and without shingles reactivation over a three-year follow-up period.

The results showed that shingles reactivation after COVID-19 was associated with a significantly increased three-year risk of several neurological disorders.

• The risk of Bell’s palsy increased early and remained consistently elevated throughout the study period.
• Patients showed more than three times the risk compared to those without herpes reactivation.
• The risks of GBS and MG also increased, although these associations appeared later, emerging after the first year of follow-up.

The study suggests that post-COVID shingles "may serve as a clinically relevant marker of neuro-immunological vulnerability, particularly among individuals with metabolic comorbidities", the team said.

Importantly, the researchers noted that "COVID-19 vaccination was not linked to an increased risk of these neurological outcomes".

US FDA Blocked Study Showing COVID And Shingles Vaccines Are Safe

Read More: Donald Trump To Undergo 3rd Annual Medical Check-up Today

Meanwhile, in recent news, officials at the US Food and Drug Administration (FDA) blocked the publication of several studies supporting the safety of widely used vaccines against COVID-19 and shingles in recent months, according to a spokesman for the Department of Health and Human Services (HHS).

While the studies found serious side effects to be very rare, the HHS said they were pulled over concerns about their conclusions. These withdrawals aim to limit access to vaccines, reflecting broader policy changes under US Health Secretary Robert F. Kennedy Jr., a staunch critic of vaccines.

“The studies were withdrawn because the authors drew broad conclusions that were not supported by the underlying data. The FDA acted to protect the integrity of its scientific process and ensure that any work associated with the agency meets its high standards,” said Andrew Nixon, a spokesman for the HHS, which oversees the FDA, in an email to Reuters.

“The design of that study fell outside the agency’s purview,” Nixon said on rejecting the shingles vaccine.